Jump Start Shared Medical Appointments for Diabetes With Weight Management

Not Applicable

Completed

• Conditions: Diabetes
• Interventions: Behavioral: Weight management; Behavioral: Shared medical appointments (SMA)

• Registration Number: NCT01973972
• Lead Sponsor: VA Office of Research and Development

Brief Summary

The proposed research will test a novel program that combines intensive weight management with shared (group) medical appointments for patients with diabetes. This research is important because diabetes is increasingly prevalent, it requires complex management by the provider and the patient, and weight loss is a critical component of its management. Adding weight management to shared medical appointments could potentially improve blood sugar control while reducing medications and their side effects such as low blood sugar.

Detailed Description

Anticipated Impacts on Veteran's Healthcare: Weight management is an important focus of VA as evidenced by its VA/DoD Clinical Practice Guideline and MOVE! program targeting overweight/obesity. VA is also committed to using group visits to increase the efficiency and effectiveness of health care delivery. The investigators aim to test a novel intervention that combines intensive weight and diabetes management using the SMA platform. This research addresses important missions to VA because diabetes is more prevalent in Veterans than in the general population, and because weight management is more challenging and complex in patients with diabetes. Project Background: SMAs involve groups of patients who share a common chronic condition and meet over time to receive education, self-management enhancement, and medication management to improve clinical outcomes. A systematic review by VA found that SMAs modestly improve glycemia in patients with diabetes. Although these SMA programs sometimes included diet and physical activity counseling, weight management was not a primary goal, and weight typically was not reduced. Instead, medication intensification was the primary strategy for improving glycemia, and this strategy can lead to weight gain.

For overweight patients with diabetes, weight loss is first-line therapy because it can improve glycemic control and because excess weight leads to poorer outcomes. Moreover, many antiglycemic medications cause weight gain and hypoglycemic events, which may counteract the potential macrovascular benefits of glycemic control. Dietary interventions, however, can lower weight and improve glycemic control while reducing antiglycemic medication needs and, therefore, subsequent risk for hypoglycemic episodes.

In prior research, the investigators induced weight loss and improved glycemic control while decreasing antiglycemic medications. A combination of an intensive weight management program with the diabetes management offered in SMAs has potential to further improve diabetes outcomes, reduce complications, decrease costs and increase health-related quality of life. Such a combined intervention is ideal for patients with diabetes because of their unique dietary considerations, and their need for careful glycemic and medication management during weight loss. Project Objectives: The investigators will examine whether an intensive, group-based weight management program followed by an SMA intervention (WM/SMA arm) is comparably effective (non-inferior) to the SMA intervention alone for improving glycemic control while using less antiglycemic medication and resulting in fewer hypoglycemic events and lower healthcare costs. Project Methods: 308 overweight VA outpatients with uncontrolled (hemoglobin A1c 8.0% or 7.5% or greater for those under 50) type 2 diabetes will participate in this RCT. Similar to prior SMAs, the SMA visits will occur every 4 weeks for 16 weeks and then every 8 weeks for 32 weeks for a total of 9 visits. Sessions will be led by a physician and trained interventionists, and will include educational topics related to diabetes management (including diet and physical activity), self-management training, and medication adjustment. Similar to the investigators' prior weight management trials, the WM/SMA group will meet every 2 weeks for 16 weeks and then every 8 weeks for 32 weeks for a total of 13 visits. The weight management program will focus on a low carbohydrate dietary pattern because of its potential to lower glycemia, leading to reduced antiglycemic medication needs. After 16 weeks, meeting content will shift to the SMA intervention content but weight management will continue to be addressed at the meetings. The primary outcome is glycemic control assessed by hemoglobin A1c assessed at baseline and at 16, 32, and 48 weeks. Secondary outcomes include hypoglycemic events, changes in the antiglycemic medication regimen as assessed by a summary score, weight and healthcare costs. Diabetes-specific health-related quality of life and medication adherence will also be assessed.

Study Timeline

• Study First Submitted: 2013-10-18
• Study First Submitted QC: 2013-10-25
• Study First Posted: 2013-11-01
• Study Start: 2014-12-12
• Primary Completion: 2018-07-31
• Study Completion: 2018-07-31
• Results First Submitted: 2019-06-27
• Results First Submitted QC: 2019-08-12
• Results First Posted: 2019-09-16
• Status Verified: 2023-07
• Last Update Submitted: 2023-07-19
• Last Update Posted: 2023-07-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 263

Inclusion Criteria

• Diagnosis of type 2 diabetes,
• Hemoglobin A1c >= 8.0% or , >= 7.5 for those less than 50
• BMI >= 27 kg/m2,
• Interest in losing weight,
• Agrees to attend regular visits per study protocol,
• Has access to reliable transportation,
• Has a VAMC provider.

Read More

Exclusion Criteria

• Age >= 75 years old,

• Hemoglobinopathy that interferes with measurement of hemoglobin A1c,

• Certain chronic or unstable diseases that may put the participant at increased risk. These include the following:

  • Kidney disease (serum creatinine >1.5 mg/dL in men, >1.3 mg/dL in women),
  • Type 1 diabetes,
  • Unstable CHD (unstable angina, current/active coronary ischemia workup),
  • Blood pressure 160/100 mm Hg,
  • Fasting triglycerides 600 mg/dL,
  • Fasting serum LDL-C 190 mg/dL,

• Pregnancy, breastfeeding, or lack of birth control if premenopausal,

• Dementia, psychiatric illness, or substance abuse that may interfere with adherence (e.g. illness that is currently unstable or resistant to first-line therapy; substance abuse in the past year),

• Enrollment in another research study that might affect the main outcomes of this study.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Weight management/shared medical appointment (WM/SMA)	Weight management	Weight management group visits every 2 weeks for 16 weeks using low-carbohydrate diet followed by group visits every 8 weeks (total of 48 weeks) for weight and diabetes management.
Weight management/shared medical appointment (WM/SMA)	Shared medical appointments (SMA)	Weight management group visits every 2 weeks for 16 weeks using low-carbohydrate diet followed by group visits every 8 weeks (total of 48 weeks) for weight and diabetes management.
Shared medical appointments (SMA)	Shared medical appointments (SMA)	Diabetes management group visits every 4 weeks for 16 weeks followed by group visits every 8 weeks (total of 48 weeks) for diabetes management.

Primary Outcome Measures

Name	Time	Method
Hemoglobin A1c	48 weeks	measure of glycemic control

Secondary Outcome Measures

Name	Time	Method
Hypoglycemic Events	through 48 weeks	All episodes of hypoglycemia will be recorded by participants on provided standard log forms, noting the date, time, duration, symptoms, treatment received, and concurrent blood glucose. Participants will additionally be asked if they received medical attention for hypoglycemia, and the details if so, since the last assessment. Only one episode will be counted per 24 hours. Serious episodes, defined as \<50 mg/dL or 50-69 mg/dL and requiring assistance, will supersede minor episodes in this case.
Medication Effect Score	48 weeks	Antiglycemic medications, dosages, and schedules will be assessed carefully with the participant and updated at each visit. A Medication Effect Score (MES), based on the potencies and dosages of the medications in a patient's regimen, was devised to reflect the overall intensity of antiglycemic medication. The MES is calculated as the percentage taken of the maximum dose multiplied by the expected hemoglobin A1c lowering effect for each of a participant's medications, which are then summed. Its range is 0 to infinite, with higher scores meaning higher diabetes medication requirement.
Weight	48 weeks	weight by electronic scale
Estimated Costs of Intervention Strategies	through 48 weeks	Estimates of intervention costs, utilities, direct and indirect costs using market lab cost estimates

Trial Locations

Locations (1)

Durham VA Medical Center, Durham, NC; 🇺🇸 Durham, North Carolina, United States